Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath - Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

Go online to PeerView.com/VAY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss the most recent clinical evidence supporting modern antibody options in acute lymphoblastic leukemia (ALL), explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Upon completion of this activity, participants should be better able to: Discuss current practice guidelines illustrating the role of antibody therapy in the management of newly diagnosed or relapsed/refractory ALL, including in Ph-negative or -positive disease, as a pretransplant strategy, or in patients with residual disease, Cite current evidence surrounding innovative antibody-based approaches, including antibody–drug conjugates and bispecific antibodies, in the management of ALL, Select evidence-based regimens with antibody components for the management of patients with ALL, Manage safety considerations related to the use of antibody therapy in patients with Ph-negative or -positive ALL.